To be added, the early CLs on HIV drugs in several African countries. South Africa 2013 2003: CPTech’s 2003 reports for the RSA Competition Commission, in Hazel Tau et al.v GSK, Boehringer, et al. CPTech was the consultant to the… Continue Reading →
EU For an earlier survey, see: 2014:1 KEI Research Note: Recent European Union Compulsory Licenses. 2014-03-01 DG-Enterprise – data exclusivity prevents access to life saving drugs (in the EU), even in an emergency situation, 2012-07-31 Germany German Court Issues Compulsory… Continue Reading →
Pages on the 2012-2013 NIH Request November 1, 2013. NIH rejects March-In petition, also rejects proposed rules on pricing of and access to government funded inventions. October 15, 2013. 15 frequently asked questions about the 2012 ritonavir March-In petition October… Continue Reading →
PhRMA and BIO have both requested that the US Trade Representative place the European Union on its watch list in the 2018 Special 301 Report. The Special 301 Report is a yearly review by the US Trade Representative of the… Continue Reading →
USDOJ 2017 UPDATE OF THE ANTITRUST GUIDELINES FOR THE LICENSING OF INTELLECTUAL PROPERTY STANDARD SETTING AND COMPETITION November 8, 2012 COMPETITION, INNOVATION AND INTELLECTUAL PROPERTY, April 26, 2012 CHAPTER 6 : COMPETITIVE ISSUES REGARDING PRACTICES THAT EXTEND THE MARKET POWER… Continue Reading →
In the area of Transparency, KEI works on several different topics, including for example: Norm setting. KEI has advocated access to meeting venues, timely disclosures of negotiating texts, and the use of webcasting of meetings, among other measures. Trade negotiations… Continue Reading →
Knowledge is essential for so many human activities and values, including freedom, the exercise of political power, and economic, social and personal development. Patents, copyright laws and other regulations and economic systems that concern the creation, management and governance of… Continue Reading →
High Level Timelines of privileges regarding the commercialization and use of knowledge Timeline of privileges regarding the commercialization and use of knowledge: Part 1: before 1980 Timeline of privileges regarding the commercialization and use of knowledge: Part 2: 1980 to… Continue Reading →
(More on compulsory licensing here.) This is a non-exhaustive set of provisions in US statutes that are used to for non-voluntary use of patented inventions. 28 U.S.C. 1498 – Patent and copyright cases (a) Whenever an invention described in and… Continue Reading →
This does not yet have links to the TPP11 negotiations and agreement, after the US left. The May 11, 2015 consolidated text on the Intellectual Property Chapter of the TPP, with country positions. August 4, 2015 Press Release The May… Continue Reading →